GX-051 / Genexine - LARVOL DELTA

Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Genexine, Inc. | Unknown status ➔ Completed

Trial completion • Gene Therapies • Head and Neck Cancer • Oncology • Solid Tumor • IL12A